PMID- 33401355
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210116
IS  - 2093-4777 (Print)
IS  - 2093-6931 (Electronic)
IS  - 2093-4777 (Linking)
VI  - 24
IP  - 4
DP  - 2020 Dec
TI  - Potential Role of Monocyte Chemoattractant Protein-1 in Monitoring Disease 
      Progression and Response to Treatment in Overactive Bladder Patients.
PG  - 341-348
LID - 10.5213/inj.2040366.183 [doi]
AB  - PURPOSE: To compare urinary levels of monocyte chemoattractant protein-1 (MCP-1), 
      an inflammatory cytokine, in healthy controls and overactive bladder (OAB) 
      patients, to correlate changes in urinary MCP-1 with OAB treatment response and 
      symptom severity, and to study the diagnostic potential of MCP-1 for OAB, as well 
      as the efficacy of MCP-1 as a potential biomarker for different phenotypes of 
      OAB. METHODS: We used enzyme-linked immunosorbent assay to measure normalized 
      urinary MCP-1 levels in 56 individuals (43 OAB patients and 13 controls). We 
      assessed the OAB patients at 3 visits with 2 validated symptom severity 
      questionnaires (OAB-V8 and Patient Perception of Bladder Condition). RESULTS: The 
      mean pretreatment urinary MCP-1 level at visit 1 (229.2-pg/mg creatinine) was 
      significantly greater than the MCP-1 levels at visit 3 in both the treatment 
      (107.0-pg/mg creatinine) (P<0.001) and control (52.35-pg/mg creatinine) groups 
      (P<0.001). Average OAB symptom severity decreased significantly from visit 1 
      (baseline) to visits 2 (4 weeks) and 3 (12-14 weeks) and was significantly 
      correlated with urinary MCP-1 levels. Urinary MCP-1 levels dropped significantly 
      (P=0.002) posttreatment in patients whose symptom severity improved by >30%, 
      whereas nonresponders displayed no significant MCP-1 decrease (P=0.164). The 
      receiver operating characteristic analysis of the OAB visit 1 and control groups 
      produced an area under the curve of 0.891. We found no significant differences in 
      sex, race, or age between the OAB and control groups. CONCLUSION: MCP-1 levels 
      differed significantly between the control and OAB groups and were closely 
      correlated with symptom severity and treatment response. The good diagnostic 
      accuracy of MCP-1 for OAB suggests the potential usage of MCP-1 for OAB 
      diagnosis. The varying response of urinary MCP-1 levels to treatment may indicate 
      at least 2 potential phenotypes of OAB. MCP-1, in combination with other 
      biomarkers and symptom severity questionnaires, could potentially aid in 
      developing a patient-centered OAB treatment approach.
FAU - Ghoniem, Gamal
AU  - Ghoniem G
AD  - Department of Urology, University of California, Irvine (UCI), Orange, CA, USA.
FAU - Farhan, Bilal
AU  - Farhan B
AD  - Department of Urology, University of California, Irvine (UCI), Orange, CA, USA.
AD  - Urology Division, Medical Branch (UTMB), University of Texas, Galveston, TX, USA.
FAU - Csuka, David
AU  - Csuka D
AD  - Department of Urology, University of California, Irvine (UCI), Orange, CA, USA.
FAU - Zaldivar, Frank
AU  - Zaldivar F
AD  - UCI Institute for Clinical & Translational Science (ICTS), Irvine, CA, USA.
LA  - eng
GR  - UL1 TR001414/TR/NCATS NIH HHS/United States
GR  - RR/NCRR NIH HHS/United States
GR  - UL1 TR001414/NH/NIH HHS/United States
PT  - Journal Article
DEP - 20201231
PL  - Korea (South)
TA  - Int Neurourol J
JT  - International neurourology journal
JID - 101534513
PMC - PMC7788331
OTO - NOTNLM
OT  - Chemokine CCL2
OT  - Cytokines
OT  - Urinary bladder, Overactive
COIS- Conflict of Interest Gamal Ghoniem: Research grant (Cogentix/Laborie), 
      Consulting: RebeccaTech and Boston Scientific. Bilal Farhan, David Csuka, Frank 
      Zaldivar: have no conflicts of interest to disclose.
EDAT- 2021/01/07 06:00
MHDA- 2021/01/07 06:01
PMCR- 2020/12/01
CRDT- 2021/01/06 00:12
PHST- 2020/06/11 00:00 [received]
PHST- 2020/11/08 00:00 [accepted]
PHST- 2021/01/06 00:12 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/01/07 06:01 [medline]
PHST- 2020/12/01 00:00 [pmc-release]
AID - inj.2040366.183 [pii]
AID - inj-2040366-183 [pii]
AID - 10.5213/inj.2040366.183 [doi]
PST - ppublish
SO  - Int Neurourol J. 2020 Dec;24(4):341-348. doi: 10.5213/inj.2040366.183. Epub 2020 
      Dec 31.